Literature DB >> 31698448

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Margherita Maffioli1, Toni Giorgino2,3, Barbara Mora1, Alessandra Iurlo4, Elena Elli5, Maria Chiara Finazzi6, Marianna Caramella7, Elisa Rumi8, Maria Cristina Carraro9, Nicola Polverelli10, Mariella D'Adda11, Simona Malato12, Marianna Rossi13, Alfredo Molteni14, Alessandro Vismara15, Cinzia Sissa16, Francesco Spina17, Michela Anghilieri18, Daniele Cattaneo4, Rossella Renso5, Marta Bellini6, Maria Luisa Pioltelli7, Chiara Cavalloni8, Daniela Barraco1, Raffaella Accetta19, Lorenza Bertù20, Matteo Giovanni Della Porta13, Francesco Passamonti20.   

Abstract

Entities:  

Year:  2019        PMID: 31698448      PMCID: PMC6855128          DOI: 10.1182/bloodadvances.2019000646

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  16 in total

1.  A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database.

Authors:  Andrew M Brunner; Gabriela Hobbs; Marla M Jalbut; Donna S Neuberg; Amir T Fathi
Journal:  Leuk Lymphoma       Date:  2015-08-19

2.  Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Authors:  Elisa Rumi; Silvia Zibellini; Emanuela Boveri; Chiara Cavalloni; Roberta Riboni; Ilaria Carola Casetti; Michele Ciboddo; Chiara Trotti; Cristina Favaron; Daniela Pietra; Chiara Candido; Virginia Valeria Ferretti; Mario Cazzola; Luca Arcaini
Journal:  Am J Hematol       Date:  2019-05-01       Impact factor: 10.047

3.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.

Authors:  Haifa Kathrin Al-Ali; Martin Griesshammer; Philipp le Coutre; Cornelius F Waller; Anna Marina Liberati; Philippe Schafhausen; Renato Tavares; Pilar Giraldo; Lynda Foltz; Pia Raanani; Vikas Gupta; Bayane Tannir; Julian Perez Ronco; Jagannath Ghosh; Bruno Martino; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

6.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

7.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

8.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

10.  Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Authors:  Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

View more
  4 in total

1.  Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.

Authors:  Katsuhiro Fukutsuka; Futoshi Iioka; Fumiyo Maekawa; Miho Nakagawa; Chiyuki Kishimori; Masahiko Hayashida; Shunsuke Tagawa; Takashi Akasaka; Gen Honjo; Hitoshi Ohno
Journal:  J Clin Exp Hematop       Date:  2021-05-14

2.  Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Authors:  Rohit Sekhri; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Karlo Huenerbein; Raphael Meixner; Hannah Marchi; Rudolf Wallmann; Christiane Fuchs; Martin Griesshammer; Kai Wille
Journal:  Ann Hematol       Date:  2021-08-31       Impact factor: 3.673

3.  A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.

Authors:  Margherita Maffioli; Barbara Mora; Somedeb Ball; Alessandra Iurlo; Elena Maria Elli; Maria Chiara Finazzi; Nicola Polverelli; Elisa Rumi; Marianna Caramella; Maria Cristina Carraro; Mariella D'Adda; Alfredo Molteni; Cinzia Sissa; Francesca Lunghi; Alessandro Vismara; Marta Ubezio; Anna Guidetti; Sabrina Caberlon; Michela Anghilieri; Rami Komrokji; Daniele Cattaneo; Matteo Giovanni Della Porta; Toni Giorgino; Lorenza Bertù; Marco Brociner; Andrew Kuykendall; Francesco Passamonti
Journal:  Blood Adv       Date:  2022-03-22

Review 4.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.